source
- Phase 1 trial shows safety and early PSA responses for novel PSMA radioligand in mCRPCA Phase 1 study evaluated the long‑circulating PSMA therapeutic radioligand [177Lu]Lu‑D‑Dan‑Phe‑PSMA in patients with metastatic castration‑resistant prostate cancer. The trial enrolled several dos…
- Pfizer, Arvinas sell recently approved breast cancer drug to Rigel for $35 millionPfizer and its partner Arvinas have agreed to transfer the commercial rights of a breast cancer therapy to Rigel Pharmaceuticals. The drug had just received regulatory approval, marking a mileston…